5 results about "Ritonavir" patented technology

Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.

The present application relates to a kind of combination drug composition for preventing or treating diffuse large B-cell lymphoma and its application, the active component of the combination drug composition is composed of first active component and second active component;The first active component is selected from selinexor or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite;The second active component is selected from ritonavir or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite.The combination drug composition has excellent treatment effect of diffuse large B-cell lymphoma, not only can reduce the dosage of selinexor, improve the safety of drug, but also has more significant inhibitory effect on diffuse large B-cell lymphoma than using single selinexor.

The application belongs to the technical field of pharmaceutical preparations, and discloses a liquid preparation containing nirmatrelvir and ritonavir as well as a preparation method and application thereof. The liquid preparation is prepared by combining nirmatrelvir, ritonavir and other excipients, has high absorption and high bioavailability, is accurate in dosing, and can accurately give a reasonable dose according to different symptoms. The application solves the problems of the existing Paxlovid tablet, such as large dose, inconvenience in taking, low dissolution, low bioavailability and the need to take multiple tablets, improves the medication compliance of patients, and reduces the drug toxicity. The preparation process of the liquid preparation containing nirmatrelvir and ritonavir is simple, and large equipment is not needed. The liquid preparation containing nirmatrelvir and ritonavir retains the medicinal properties of nirmatrelvir and ritonavir, and can be used for preparing a drug for novel coronavirus.

To provide compositions and kits of antiviral agents having different mechanisms of action for treating or preventing viral infections such as COVID-19 (also known as SARS-CoV-2) and for reducing medical complications related to COVID-19 viral disease.SOLUTION: A pharmaceutical composition for treating COVID-19 is provided, comprising: a first antiviral agent consisting of a picornavirus 3C protease inhibitor or a pharmaceutically acceptable salt thereof in a therapeutically effective amount; a second antiviral agent consisting of ritonavir or a pharmaceutically acceptable salt thereof in a therapeutically effective amount and having a different mechanism of action; and a third antiviral agent selected from a group consisting of dexamethasone and remdesivir.SELECTED DRAWING: None

The present disclosure is related to a polymorphic form of ritonavir prepared by novel methods that require less time to produce the polymorphic form, the methods of preparing the polymorphic form, pharmaceutical compositions comprising the polymorphic form produced by the provided methods, and corresponding methods of treatment with the polymorphic form produced by the provided methods.